Peptide Profit Margins: What to Expect

Peptides are pitched as an 80 percent margin business. The gross margin number is real. The problem is that gross margin in this category is roughly meaningless, because the cost structure that eats it sits below the gross margin line: high-risk processing, restricted-category acquisition costs, and reserve locking up your cash. Here are the numbers that actually run the business.

gross margin by model

• —RUO ecommerce: $8 to $22 landed against $45 to $95 retail. Gross margin 75 to 88 percent.
• —Clinical monthly program: $150 to $260 cost against $299 to $549 retail. Gross margin 45 to 65 percent.
• —Med spa in-clinic dispensing: similar to clinical, sometimes better if you buy office stock at volume where permitted.
• —Private label wholesale to other clinics: 30 to 45 percent gross margin, much lower acquisition cost, much higher order size.

Notice that the highest gross margin model has the lowest dollar contribution per order. An 85 percent margin on a $55 vial is $47. A 55 percent margin on a $399 program is $219. That is why med spas that add an online channel outrun pure RUO stores on the same ad budget.

contribution margin: the number that matters

Contribution margin is what is left after every variable cost, including acquisition. Work a realistic RUO order:

1. 1.Order value: $165 (a three-vial bundle).
2. 2.Product cost: $46.
3. 3.Fulfillment: $9.
4. 4.Processing at 4.5 percent plus $0.30: $7.73.
5. 5.Breakage, reships, support: $6.
6. 6.Blended CAC: $55.
7. 7.Contribution margin: $41.27, or 25 percent of revenue.

That is a healthy first order in this category. Now run the same math on a single $55 vial: $16 product, $8 fulfillment, $2.78 processing, $4 support, $55 CAC. You are down $30.78 on the order. Same gross margin percentage, completely different business.

repeat purchase is where the margin actually comes from

The second order has no acquisition cost. In the example above, the second $165 order carries $46 product, $9 fulfillment, $7.73 processing, $6 support, and $0 CAC, producing $96.27 of contribution, or 58 percent. A customer who orders three times in a year produces $233 of contribution against a $55 acquisition cost.

So the actual profit lever in a peptide business is not price and it is not COGS. It is repeat purchase rate. Everything you do operationally should aim at it:

• —Subscribe and save on every eligible SKU, promoted at checkout and in post-purchase email.
• —Replenishment flows timed to actual usage cycles, not generic 30-day sends.
• —Fast, reliable delivery. Late first deliveries are the single largest predictor of non-repeat.
• —Real support with a human. This category generates questions and unanswered questions become refunds.
• —Published lot testing that gives the customer a reason to stop shopping around.

net margin: what actually reaches the bottom line

Subtract fixed costs from contribution: software, 3PL minimums, salaries and contractors, legal and testing, insurance, and creative production. For a business doing $100,000 a month, fixed costs typically run $12,000 to $25,000. Against roughly $30,000 to $40,000 of contribution at a 30 to 40 percent rate, that leaves a net margin of 10 to 25 percent.

At $500,000 a month, fixed costs might rise to $50,000 to $90,000 while contribution scales linearly, so net margin expands to 20 to 30 percent. This is a business with real operating leverage, which is why the operators who push through the first six months tend to do very well.

what ad performance does to the whole model

CAC is the largest single variable in the equation, which means media efficiency is the biggest margin lever you have. The difference between a 2.0 blended ROAS and a 4.0 blended ROAS is not a 2x improvement in profit, it is often the difference between losing money and making 30 percent net.

For reference points: WayyLess ran $4.3M in spend to $19.1M in revenue at 4.45 blended ROAS. AC-NEXTGEN top creatives ran 7.5 to 16 ROAS, with a single ad returning $53,269 on $6,049. Goodscience had one creative return $33,225 on $8,664. LIVV Well grew over 1,200 percent in six months with top creatives at 6.79 to 14.96 ROAS. Those are top-creative and blended numbers on well-run accounts, not averages you should budget against on day one, but they show the ceiling.

the margin killers

• —Chargebacks. At 1 percent of volume plus $35 per instance, and with the threat of processor termination behind them, they cost far more than the disputed revenue.
• —Stockouts. Losing ad momentum costs more than the missed orders, because rebuilding the learning phase is expensive.
• —Discounting into a corner. Standing sitewide discounts permanently reset your price anchor and take 8 to 12 points off net.
• —Reserve drag. Cash locked at 5 to 10 percent for 180 days constrains restocking exactly when you are growing fastest.
• —Creative fatigue. As CPMs climb and CTR falls, CAC rises quietly and margin evaporates before anyone notices.
• —Over-SKUing. Every additional SKU adds testing, inventory, and carrying cost while splitting demand.

benchmarks worth tracking weekly

1. 1.Contribution margin per order, not ROAS. ROAS ignores COGS and fulfillment.
2. 2.60-day repeat purchase rate. Target 25 percent or better for RUO, 70 percent or better month-two retention for clinical programs.
3. 3.Subscription share of orders. Target 20 to 35 percent.
4. 4.Chargeback rate. Keep it under 0.5 percent, well inside network thresholds.
5. 5.Blended CAC versus 90-day contribution. If 90-day contribution is under 2x CAC, you cannot scale spend safely.

gross margin gets you in the room. contribution margin per order and repeat rate decide whether you are still in it in month twelve.

This is not financial advice, and the ranges here reflect what we see across builds rather than a guarantee. Your numbers depend on your lane, your market, and your acquisition efficiency.